GHB Withdrawal Symptoms and Treatment Options

Dr. Sheridan Walter
Dr. David Miles
Written by Dr. Sheridan Walter on 06 January 2025
Medically reviewed by Dr. David Miles on 07 January 2025

Gamma-hydroxybutyrate (GHB), although more known for illicit use, is prescribed for narcolepsy (marketed as sodium oxybate or Xyrem) and has shown potential for treating alcohol use disorder (AUD). However, its use for AUD is controversial due to the risk of dependence.

GHB and its analog Gamma-butyrolactone (GBL) have become increasingly popular in recreational settings, especially in sexualized drug use or chemsex settings among men who have sex with men. Furthermore, GHB is used as a club drug or as an alternative to alcohol due to its unique pharmacological actions of producing euphoria, relaxation, and sedation. Due to its short half-life (20-30 minutes), frequent use is necessary to sustain its effects, contributing to its high dependence potential.

GHB withdrawal is widely regarded as one of the most severe among central nervous system (CNS) depressants. GHB withdrawal symptoms begin within hours after the last dose, driven by the drug’s fast metabolism. The hyperadrenergic state, a state of uncomfortable excitability seen during GHB withdrawal, reflects a rebound from the drug’s suppression of neural excitability.

Key takeaways:
  • GHB withdrawal symptoms include physical (tremors, sweating, seizures, high blood pressure) and psychological effects (anxiety, paranoia, hallucinations, and cravings), with the potential for severe complications like delirium tremens.
  • Withdrawal symptoms begin within 1–6 hours after the last dose, peak at 48–72 hours, and last 9–10 days on average, with some lingering symptoms that may last for weeks to months.
  • Withdrawal is managed with medical supervision, using medications like benzodiazepines, baclofen, or pharmaceutical GHB tapering, with supportive care to address potential dehydration, agitation, and other complications.
a close up of a man in green long sleeves experiencing tremors on his arm, a symptom of GHB withdrawal

What is GHB withdrawal?

GHB withdrawal syndrome (GWS) can occur after stopping the use of GHB or its analogs ( like GBL) and is similar to withdrawal syndromes seen with alcohol and benzodiazepines. Because GHB has a short duration of action and is rapidly eliminated from the body, withdrawal symptoms can develop quickly within 1 to 6 hours after the last dose. These symptoms tend to escalate rapidly.

The fast oral absorption and short half-life of GHB explain why regular users often take it every 1 to 4 hours to avoid withdrawal. Withdrawal symptoms can last anywhere from 3 to 21 days, with an average duration of 9 to 10 days.

Certain factors increase the risk of withdrawal, including high and frequent doses. For example, using more than 4 mL (milliliter) of GBL daily, taking GHB/GBL more than 4–6 times daily for 2–4 weeks, or daily doses of at least 18 g of GHB or 10 g of GBL are significant predictors. Previous withdrawal episodes and polydrug use also increase the likelihood of GWS.

Most chronic users experience withdrawal symptoms after around 18 months of regular use, although symptoms can appear as early as 8–13 weeks in some cases. GHB withdrawal symptoms develop much sooner after stopping the drug compared to those seen in alcohol withdrawal. In addition, GHB withdrawal might lead to delirium tremens (DT), a life-threatening condition usually associated with alcohol withdrawal.

Why GHB withdrawal requires medical supervision

GHB withdrawal requires medical supervision due to its rapid onset, severe symptoms, and life-threatening risks. Without proper care, individuals may experience seizures, dangerous agitation, complications like kidney damage or respiratory issues, and in some cases, even death. Withdrawal symptoms, especially cravings, can also increase the likelihood of relapse.

Medical professionals can provide medications, fluid and electrolyte replacement, nutritional support, and continuous monitoring to manage symptoms.

Symptoms of GHB withdrawal

GHB withdrawal causes many complex symptoms due to its effects on the CNS. These symptoms can be mild or severe, with some, if not most, requiring medical intervention. The symptoms can be categorized into physical and psychological.

Physical symptoms:  

  • Tremors
  • Sweating
  • Muscle cramps and pain
  • Seizures
  • Nausea and vomiting
  • High blood pressure
  • Increased heart rate
  • Hyperthermia
  • Headaches
  • Sleep disturbances
  • Respiratory changes and breathing difficulty
  • Fatigue and lethargy

Psychological symptoms:  

  • Anxiety and panic attacks
  • Agitation and irritability
  • Paranoia
  • Hallucinations
  • Difficulty thinking clearly or concentrating
  • Mood swings
  • Delirium – severe confusion, often with hallucinations or disorientation.
  • Depression
  • Cravings
  • Psychosis

Initial GHB withdrawal symptoms

GHB withdrawal symptoms typically begin within hours after the last dose due to its short half-life. Physical symptoms include shaking, particularly in the hands, along with sweating, nausea, and vomiting. Individuals may also experience an increased heart rate (tachycardia), elevated blood pressure, and muscle stiffness or cramps, which contribute to physical discomfort during withdrawal.

Psychological symptoms can be equally distressing. Many individuals report feelings of unease or heightened anxiety, making it difficult to stay calm or relaxed. Sleep disturbances, including difficulty falling or staying asleep and experiencing vivid dreams, are common. Additionally, intense cravings for GHB often occur, further complicating the withdrawal process.

Acute GHB withdrawal symptoms

Acute GHB withdrawal symptoms peak within 48–72 hours after stopping and can last up to 10 days, with the severity depending on the extent of use and individual factors. These symptoms can be life-threatening and require medical intervention.

Physical symptoms during the acute phase are often severe and include a rapid heart rate (tachycardia), significantly elevated blood pressure, and profuse sweating (diaphoresis). Individuals may experience seizures and muscle breakdown (rhabdomyolysis), which can cause kidney damage. Dehydration is also common due to excessive vomiting, sweating, and inadequate fluid intake.

Psychological symptoms can be equally dangerous. Severe agitation and paranoia may lead to heightened restlessness and mistrust of others. Hallucinations, both auditory and visual, often occur alongside confusion and disorientation. In extreme cases, withdrawal can cause delirium, a serious mental disturbance that may escalate into life-threatening conditions without proper care.

Post-acute and long-term symptoms

Post-acute withdrawal from GHB can present with lingering symptoms that persist well beyond the acute withdrawal phase. These symptoms may last weeks to months. Post-acute symptoms include persistent fatigue and disrupted sleep patterns, as well as anxiety and mood swings. Many individuals report lasting depressive states, intense cravings for GHB, and difficulty concentrating or remembering things.

GHB withdrawal timeline

This table summarizes the various phases of withdrawal experienced by individuals who abruptly discontinue the use of GHB.

PhaseTimingPrimary Symptoms
Onset/Early Phase1–6 hoursTremors, sweating, mild high blood pressure, anxiety, cravings, interrupted sleep pattern.
Peak Withdrawal48–72 hoursSevere elevated heart rate, high blood pressure, agitation, hallucinations, seizures, delirium.
Extended Phase3–10 daysFatigue, lingering anxiety, cravings, brain fog, sleep difficulty.
Protracted WithdrawalWeeks to monthsTiredness, anxiety, depressive states, difficulty concentrating and thinking.

Treatment and management of GHB withdrawal

Treatment and management of GHB withdrawal focus on easing withdrawal symptoms and preventing medical complications.

Doctors typically start by administering benzodiazepines like diazepam (Valium), which help calm the nervous system and reduce symptoms like anxiety, tremors, and delirium. However, and rarely, in severe cases, the body may not respond to benzodiazepines alone, and additional treatments, like phenobarbital (a barbiturate), may be used to control symptoms. In some extreme cases, a temporary medically induced coma with medications like thiopental has been used successfully when other treatments failed.

Another promising option is baclofen, which works on the same brain receptors affected by GHB. Baclofen can be used either alongside benzodiazepines or by itself to manage withdrawal symptoms more safely, particularly in cases where large doses of benzodiazepines might be risky.

In some instances, antipsychotics are used to manage severe psychiatric withdrawal symptoms.

Then, there are cases where pharmaceutical GHB is used to taper the dose gradually. This method has been shown to reduce withdrawal severity and complications compared to benzodiazepines alone. It does come with challenges, and one of them is that it requires specialized care and expertise.

Recovery support and preventing relapse for GHB

After completing detox and therapy (either in-patient or out-patient), individuals need long-term support to maintain sobriety. This can include group therapy, 12-step programs like Narcotics Anonymous (NA), or ongoing counseling. Having a long-term recovery plan helps people stay on track and avoid the triggers that may lead them back to GHB use. Furthermore, having a strong support structure is highly advantageous.

FAQs

Common questions about GHB withdrawal

How long does GHB withdrawal last?

Withdrawal symptoms typically last 9–10 days on average. However, depending on individual factors, the duration can range from 3 to 21 days.

Can GHB withdrawal be life-threatening?

Yes, GHB withdrawal can be life-threatening, especially if you use GHB or GBL daily and frequently and if this is for an extended period.

Can I withdraw from GHB myself at home?

It is possible, but it's not recommended at all due to the severe risks associated with GHB withdrawal syndrome.

What medications help with GHB withdrawal?

Medications commonly used include:

  • Benzodiazepines (e.g., diazepam) used to calm the CNS.
  • Baclofen targets the same receptors as GHB.
  • Phenobarbital is recommended for severe cases that do not respond to benzodiazepines.
  • Antipsychotics are sometimes given for severe agitation or psychosis.
  • Pharmaceutical GHB is administered in controlled medical settings for gradual tapering.
Was this page helpful?

Your feedback allows us to continually improve our information

Resources:

  1. U.S. Food and Drug Administration. (2017, January 25). Xyrem (sodium oxybate) information. Retrieved from
  2. Caputo, F. (2011). Gamma-hydroxybutyrate (GHB) for the treatment of alcohol dependence: a call for further understanding. Alcohol and alcoholism, 46 1, 3. Retrieved from
  3. Busardò, F. P., Gottardi, M., Tini, A., Minutillo, A., Sirignano, A., Marinelli, E., & Zaami, S. (2018). Replacing GHB with GBL in Recreational Settings: A New Trend in Chemsex. Current drug metabolism, 19(13), 1080–1085. Retrieved from
  4. Teter, C. J., & Guthrie, S. K. (2001). A Comprehensive Review of MDMA and GHB: Two Common Club Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 21(12), 1486-1513. Retrieved from
  5. Karila, L., Angerville, B., Benyamina, A., et al. (2024). Pharmacological treatment of GHB withdrawal syndrome. Current Addiction Reports, 11(1), 163–171. Retrieved from
  6. Galloway, G. P., Frederick, S. L., Staggers Jr, F. E., Gonzales, M., Stalcup, S. A., & Smith, D. E. (1997). Gamma‐hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction, 92(1), 89-96. Retrieved from
  7. Brunt, T. M., van Amsterdam, J. G. C., & van den Brink, W. (2014). GHB, GBL, and 1,4-BD addiction. Current Pharmaceutical Design, 20(25), 4076–4085. Retrieved from
  8. McDonough, M., Kennedy, N., Glasper, A., & Bearn, J. (2004). Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug and alcohol dependence, 75 1, 3-9. Retrieved from
  9. Van Noorden, M., Van Dongen, L., Zitman, F., & Vergouwen, T. (2009). Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. General hospital psychiatry, 31 4, 394-6. Retrieved from
  10. Supady, A., Schwab, T., & Busch, H.-J. (2009). „Liquid Ecstasy”: Gamma-butyrolactone withdrawal delirium with rhabdomyolysis and dialysis-dependent renal failure. Dtsch Med Wochenschr, 134(18), 935–937. Retrieved from
  11. Dyer, J., Roth, B., & Hyma, B. (2001). Gamma-hydroxybutyrate withdrawal syndrome. Annals of Emergency Medicine, 37 2, 147-53. Retrieved from
  12. Wolf, C., Beurmanjer, H., Dijkstra, B., Geerlings, A., Spoelder, M., Homberg, J., & Schellekens, A. (2021). Characterization of the GHB Withdrawal Syndrome. Journal of Clinical Medicine, 10. Retrieved from
  13. Craig, K., Gomez, H., Mcmanus, J., & Bania, T. (2000). Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. The Journal of Emergency Medicine, 18 1, 65-70. Retrieved from
  14. Harris, K., Harburg, G., & Isoardi, K. (2020). When fantasy fades: A case of severe delirium due to GHB withdrawal. Emergency Medicine Australasia, 32. Retrieved from
  15. Freeman, G., Siefried, K., Roberts, D., Rodgers, C., Ionmhain, U., Ramanathan, J., Ezard, N., & Brett, J. (2022). Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series. Drug and alcohol review. Retrieved from
  16. Vos, C., Pop-Purceleanu, M., Van Den Berg, M., & Schellekens, A. (2020). Successful Treatment of Severe, Treatment Resistant GHB Withdrawal through Thiopental-Coma. Substance Abuse, 42, 33 - 38. Retrieved from
  17. Habibian, S., Ahamad, K., Mclean, M., & Socías, M. (2019). Successful Management of Gamma-hydroxybutyrate (GHB) Withdrawal Using Baclofen as a Standalone Therapy: A Case Report. Journal of Addiction Medicine. Retrieved from
  18. Beurmanjer, H., Luykx, J., De Wilde, B., Van Rompaey, K., Buwalda, V., De Jong, C., Dijkstra, B., & Schellekens, A. (2020). Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands. CNS Drugs, 34, 651 - 659. Retrieved from

Activity History - Last updated: 07 January 2025, Published date:


Reviewer

David is a seasoned Pharmacist, natural medicines expert, medical reviewer, and pastor. Earning his Doctorate from the Medical University of South Carolina, David received clinical training at several major hospital systems and has worked for various pharmacy chains over the years. His focus and passion has always been taking care of his patients by getting accurate information and thorough education to those who need it most. His motto: "Good Information = Good Outcomes".

Activity History - Medically Reviewed on 12 December 2024 and last checked on 07 January 2025

Medically reviewed by
Dr. David Miles

Dr. David Miles

PharmD

Reviewer

Recovered Branding BG
Ready to talk about treatment? Call today. (855) 648-7288
Helpline Information

Calls to numbers marked with (I) symbols will be answered or returned by one of the treatment providers listed in our Terms and Conditions, each of which is a paid advertiser.

In calling the helpline you agree to our Terms and Conditions. We do not receive any fee or commission dependent upon which treatment or provider a caller chooses.

There is no obligation to enter treatment.

For any specific questions please email us at info@recovered.org

Related guides

Withdrawal Symptoms

9 minutes read